Skip to navigation Skip to content

Clinical Trial: Ocrelizumab in Progressive MS (CONSONANCE)

Share

Details
Type of MS: PPMS|SPMS
Treatment mode of action: To delay MS progression
Number of Subjects: 5
Medication: ocrelizumab
Location: Illinois|Indiana|Iowa|Michigan|Missouri|Wisconsin
Institutions: University of Chicago
5841 S Maryland Ave
Chicago, IL Contact Information
Please see below for contact information

Funding:

Genentech, Inc

Description

The purpose of the study is to see if Ocrelizumab will halt the worsening of the signs and symptoms of Progressive forms of MS. Smartphone-based “passive monitoring” of participants will also take place during the study. It will collect data on gait and mobility throughout the daily life of participants in a continuous and unobtrusive manner. For this, participants will be required to carry their smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine. They must carry the device for approximately four or more hours/day until it runs out of charge. 

The smartphone-based application also will prompt and self-guide the user to perform various assessments, referred to as “active tests.” These will be performed by the participants include the following and take approximately 5 minutes in total and should be performed at a consistent time each day: 
 - Cognitive, gait and posture tests.
 - Hand motor function tests: Test 1: Draw a Shape, test 2: Pinching

Participants may qualify for substudies involving MRI or optical coherence tomography (OCT).

Contact Name: Sravya Aluri or Mildred Valentine or the Study PI: Dr. Reder    
Phone: 7737044654 (Sravya) or 7737029812 (Mildred) 
Email: saluri@neurology.bsd.uchicago.edu (Sravya) or mvalenti@neurology.bsd.uchicago.edu (Mildred) or areder@neurology.bsd.uchicago.edu (Dr. Reder)

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.